Ignite Creation Date:
2024-05-05 @ 4:38 PM
Last Modification Date:
2024-10-26 @ 9:22 AM
Study NCT ID:
NCT00283322
Status:
COMPLETED
Last Update Posted:
2007-12-06
First Post:
2006-01-25
Brief Title:
Heparin Antibodies in Intensive Care Unit Patients HAICU
Sponsor:
The University of Texas Health Science Center Houston
Organization:
The University of Texas Health Science Center Houston
Study Overview
Official Title:
Heparin Antibodies in Intensive Care Unit Patients HAICU
Status:
COMPLETED
Status Verified Date:
2007-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Intensive care unit patients have multiple risk factors for venous thromboembolism Venous thromboembolism leads to significant morbidity and can be fatal Unfractionated heparin and low molecular weight heparin are commonly used to prevent venous thromboembolism Heparin induced thrombocytopenia an untoward consequence of exposure to heparin is an immune disorder that may develop in patients treated with heparin products Determining the prevalence of heparin induced thrombocytopenia and its relationship to preventive and therapeutic heparin and low molecular weight heparin will help clinicians more appropriately choose methods of venous thromboembolism prophylaxis and treatment in the critically ill ICU population
The objective of this study is to determine the prevalence of heparin-induced antibodies on admission to the ICU and the development of new heparin-antibodies during the first week of hospitalization
The objective of this study is to determine the prevalence of heparin-induced antibodies on admission to the ICU and the development of new heparin-antibodies during the first week of hospitalization
Detailed Description:
Venous Thromboembolism VTE is common in the intensive care unit ICU VTE leads to significant morbidity and is fatal in 30 of undiagnosed pulmonary emboli and 8 when PE is appropriately treated Intensive care unit ICU patients have multiple risk factors for VTE and tend to be at higher risk than non-ICU patients Risk factors specific to ICU patients include immobility central venous catheters sepsis or infection need for vasopressors mechanical ventilation surgery trauma and increasing age Guidelines exist for the prevention of VTE and VTE prophylaxis is strongly recommended Given the high rate of VTE and the attendant morbidity and mortality most ICUs routinely provide VTE prophylaxis which is individualized according to risk-benefit analysis with respect to thrombosis and bleeding risk Prophylaxis for patients at risk of bleeding is accomplished by using mechanical compression devices while those without bleeding risk are administered medical prophylaxis which is felt to be more effective
Recently it has become apparent that medical prophylaxis is not without risk and that the risk-benefit analysis should also include the risk of developing heparin induced thrombocytopenia HIT or heparin induced thrombocytopenia with thrombosis HITT
Unfractionated heparin UFH and low molecular weight heparin LMWH are commonly used to prevent VTE in ICU and non-ICU patients HIT an untoward consequence of exposure to heparin is an immune disorder that may develop in patients treated with heparin products HIT is antibody mediated usually due to IgG antibodies directed against epitopes on the platelet surface comprised of the heparin-platelet factor 4 complex HIT is generally characterized by a decrease in platelet count to less than 100 X 109L or a 50 decrease from baseline after exposure to heparin HIT is typically observed after 5 to 10 days of treatment Alternatively patients with previous exposure to heparin can develop HIT in two days while heparin naive patients may develop HIT in about 10 days The platelet count usually returns to normal several days after discontinuing heparin with or without therapy though the risk for thrombosis persists for up to 3 months due to the persistence of antibodies
Using an ELISA assay heparin-induced antibody formation is found in up to 50 of patients exposed to UFH However the serotonin release assay SRA which is believed to be more specific for HIT detects antibody formation in about 20 of patients Five percent of patients receiving UFH develop thrombocytopenia HIT and half of these patients go on to develop heparin induced thrombocytopenia with thrombosis HITT which results in venous and arterial complications which can be life threatening or result in loss of extremities
The occurrence of HIT varies widely between clinical populations and is dependent on the type of heparin used ie UFH vs LMWH The highest incidence reported to date has been in the cardiac and orthopedic populations and is unknown in the ICU population Warkentin et al found in a study of 655 hip surgery patients that 27 randomized to UFH developed HIT while none receiving enoxaparin LMWH developed HIT This variability in development of antibodies and the HIT syndrome makes it critically important to understand heparin induced antibody formation as a precursor to HIT and HITT
Determining the prevalence of HIT and its relationship to preventive and therapeutic UFH and LMWH will help clinicians more appropriately choose methods of VTE prophylaxis and treatment in the critically ill ICU population
Objectives To determine the prevalence of heparin-induced antibodies on admission to the ICU and the development of new heparin-antibodies during the first 7 - 2 days of hospitalization Secondary objectives include determining the incidence of heparin antibody formation in patients treated with UFH LMWH and mechanical prophylaxis MPX and to compare the incidence of heparin antibodies between different ICU populations
Recently it has become apparent that medical prophylaxis is not without risk and that the risk-benefit analysis should also include the risk of developing heparin induced thrombocytopenia HIT or heparin induced thrombocytopenia with thrombosis HITT
Unfractionated heparin UFH and low molecular weight heparin LMWH are commonly used to prevent VTE in ICU and non-ICU patients HIT an untoward consequence of exposure to heparin is an immune disorder that may develop in patients treated with heparin products HIT is antibody mediated usually due to IgG antibodies directed against epitopes on the platelet surface comprised of the heparin-platelet factor 4 complex HIT is generally characterized by a decrease in platelet count to less than 100 X 109L or a 50 decrease from baseline after exposure to heparin HIT is typically observed after 5 to 10 days of treatment Alternatively patients with previous exposure to heparin can develop HIT in two days while heparin naive patients may develop HIT in about 10 days The platelet count usually returns to normal several days after discontinuing heparin with or without therapy though the risk for thrombosis persists for up to 3 months due to the persistence of antibodies
Using an ELISA assay heparin-induced antibody formation is found in up to 50 of patients exposed to UFH However the serotonin release assay SRA which is believed to be more specific for HIT detects antibody formation in about 20 of patients Five percent of patients receiving UFH develop thrombocytopenia HIT and half of these patients go on to develop heparin induced thrombocytopenia with thrombosis HITT which results in venous and arterial complications which can be life threatening or result in loss of extremities
The occurrence of HIT varies widely between clinical populations and is dependent on the type of heparin used ie UFH vs LMWH The highest incidence reported to date has been in the cardiac and orthopedic populations and is unknown in the ICU population Warkentin et al found in a study of 655 hip surgery patients that 27 randomized to UFH developed HIT while none receiving enoxaparin LMWH developed HIT This variability in development of antibodies and the HIT syndrome makes it critically important to understand heparin induced antibody formation as a precursor to HIT and HITT
Determining the prevalence of HIT and its relationship to preventive and therapeutic UFH and LMWH will help clinicians more appropriately choose methods of VTE prophylaxis and treatment in the critically ill ICU population
Objectives To determine the prevalence of heparin-induced antibodies on admission to the ICU and the development of new heparin-antibodies during the first 7 - 2 days of hospitalization Secondary objectives include determining the incidence of heparin antibody formation in patients treated with UFH LMWH and mechanical prophylaxis MPX and to compare the incidence of heparin antibodies between different ICU populations
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| HAICU | None | None | None |